Cassava Sciences, Inc. (NASDAQ: SAVA)
$2.3800
+0.0300 ( +1.93% ) 373.3K
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
Market Data
Open
$2.3800
Previous close
$2.3500
Volume
373.3K
Market cap
$113.06M
Day range
$2.3150 - $2.4700
52 week range
$2.2300 - $42.2000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
3 | Insider transactions | 1 | Dec 07, 2023 |
4 | Insider transactions | 1 | Dec 07, 2023 |
4 | Insider transactions | 1 | Dec 07, 2023 |